Vanguard Capital Management
REGN icon

Vanguard Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Vanguard Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13B Sell
6,629,759
-25,154
-0.4% -$17.1M 0.09% 192
2026
Q1 		$5.14B Buy
+6,654,913
New +$5.09B 0.13% 137

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Vanguard Capital Management's REGN Position: Q2 2026 in Review

Vanguard Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 0.38% in Q2 2026, selling an estimated $17.1M and leaving 6,629,759 shares worth $4.13B. The position accounts for 0.09% of the portfolio, ranked #192.

Vanguard Capital Management first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.14B in Q1 2026. 1,256 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Vanguard Capital Management held 6,629,759 shares of Regeneron Pharmaceuticals worth $4.13B as of Q2 2026.
  • Vanguard Capital Management sold 25,154 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $17.1M.
  • Regeneron Pharmaceuticals made up 0.09% of Vanguard Capital Management's portfolio in Q2 2026, its #192 holding.
  • Vanguard Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Regeneron Pharmaceuticals position peaked at $5.14B in Q1 2026.
  • 1,256 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.